openPR Logo
Press release

Global Monoclonal Antibodies Market was valued at US$ 123.65 billion in 2020 and is expected to reach US$ 239.01 billion by 2028, growing at a CAGR of 13.1% over the forecast period

03-08-2021 01:11 PM CET | Health & Medicine

Press release from: Absolute Markets Insights

Global Monoclonal Antibodies Market was valued at US$ 123.65

Monoclonal antibodies (mAbs) are immunoglobulins that are engineered to target an antigen. At least five monoclonal antibodies per year have been approved by the FDA since 2014 and this trend shows no signs of slowing down. These treatments include a variety of indications such as autoimmune conditions, infectious diseases and oncology. One of the fastest-growing groups of prescription drugs is monoclonal antibodies. When more possible targets are identified with a better understanding the diseases the production of new mAb-based drugs provides new opportunities.

Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=796

An accurate study of Monoclonal Antibodies Market has been published by Absolute Markets Insights in order to comprehend the potential of Monoclonal Antibodies industries. Acumen business knowledge of the competent team provides a precise overview of qualitative and quantitative analysis techniques which are used to examine trade data. The erudite description focuses on up-to-date developments of top level industries .This penetrative insight particularly helps to provide the guidelines for industry progression.

The detailed research study provides qualitative and quantitative analysis of monoclonal antibodies market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=796

Key Findings of the Report:

• In application, the cancer segment will lead the market over the forecast period. Increased cancer incidence is expected to increase demand for infusion therapies, contributing to a significant growth in the market for monoclonal antibodies

• North America is projected to become dominant region in the world for monoclonal antibodies. The increasing prevalence of chronic diseases has contributed to an increasing demand for these therapies. The growing number of strategic partnerships and funding for these therapies will also boost the growth of the market in this region.

• Growth in the European market will be driven by the presence of multiple healthcare reimbursement policies. In addition, the increasing prevalence of diseases such as arthritis and inflammatory illnesses will contribute to market growth.

• The major players operating in the Monoclonal Antibodies Market include Amgen Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED., Eli Lilly & Co. (acquired ImClone Systems, Inc.), F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc. and other market participants

Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=796

Monoclonal Antibodies Market:

By Source

o Murine
o Chimeric
o Humanized
o Human

By Type
o Naked Monoclonal Antibodies
o Conjugated Monoclonal Antibodies
o Bispecific Monoclonal Antibodies
o Others

By Clinical Trial Phases
o Phase 0
o Phase I
o Phase II
o Phase III
o Phase IV

By Application
o Diagnostic Testing
o Autoimmune Diseases
o Cancer Treatment
o Breast Cancer
o Stomach Cancer
o Others
o Pregnancy Testing
o Radioimmunodetection (RID) of Cancer
o Radioimmunotheraphy (RIT) of Cancer
o Viral Disease Treatment
o Identifying Pathogens
o Alzheimer’s disease
o Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma
o Rhesus Disease Immunization
o Systemic Lupus Erythematosus
o Crohn's Disease
o Ulcerative Colitis
o Psoriasis and Rheumatoid Arthritis
o Cardiovascular Disease
o Others

By End Use
o Hospitals
o Clinics
o Research Institutes
o Others

Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/Monoclonal-Antibodies-Market-2020---2028-796

About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …

Contact Us:
Email id: sales@absolutemarketsinsights.com
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424

Useful Content Rich Related Links:

Immuno-Oncology Assays Market:
https://www.absolutemarketsinsights.com/reports/Immuno-oncology-Assays-2020---2028-806

Biopharmaceutical Contract Manufacturing Market:
https://www.absolutemarketsinsights.com/reports/Global-Biopharmaceutical-Contract-Manufacturing-Market-2019-2027-287

For more Such Reports Visit: https://www.absolutemarketsinsights.com/

Contact Us:

Email id: sales@absolutemarketsinsights.com
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424

About Us:

Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Monoclonal Antibodies Market was valued at US$ 123.65 billion in 2020 and is expected to reach US$ 239.01 billion by 2028, growing at a CAGR of 13.1% over the forecast period here

News-ID: 2253496 • Views: 196

More Releases from Absolute Markets Insights

What to expect from the Litigation Funding Investment Market and know the Market …
Global Litigation Funding Investment Market was Valued at US$ 10,916.3 Mn in 2018 and is Expected to Reach US$ 22,373.3 Mn by 2027 Growing at a CAGR of 8.3% Over The Forecast Period Owing to Litigation Funding Investments Being Uncorrelated with Market Cycles, says Absolute Markets Insights Erudite analysis study of report titled Litigation Funding Investment Market has published by Absolute Markets Insights. The report provides statistical analysis thus providing crucial
What to expect from the Smart Soap Dispenser Market and know the Market scenario …
Global Smart Soap Dispenser Market is expected to grow at a CAGR of 13.5% over the Forecast Period, Owing to Surging Demand for Contactless Soap Dispensing Solution to Ensure Optimum Hygiene, says Absolute Markets Insights Erudite analysis study of report titled Smart Soap Dispenser Market has published by Absolute Markets Insights. The report provides statistical analysis thus providing crucial information on economic factors such as price, shares, revenue. The global
What to expect from the Remote Monitoring and Control System Market and know the …
Remote Monitoring and Control System Market Was Estimated to be US$ 74,897.4 Mn in 2018 and is Growing at a CAGR of 10.3% Over the Forecast Period, Says Absolute Markets Insights Remote Monitoring and Control System Market Owing to Increasing Demand for Advanced Monitoring Systems as a Result of Progressing Automation in Industries Erudite analysis study of report titled Remote Monitoring and Control System Market has published by Absolute Markets Insights.
A New Report States Facts & Figures behind Boom of the Global Hydroxychloroquine …
Hydroxychloroquine Market was estimated to be US$ 41.3 Mn in 2018 and is growing at a CAGR of 10.4% over the Forecast Period, Owing to Increasing Demand for Medications to Treat Autoimmune Diseases, says Absolute Markets Insights Some of the players operating in the hydroxychloroquine market are Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories, Inc, Ipca Laboratories Ltd. Erudite analysis study of report titled Global Hydroxychloroquine Market has published by Absolute Markets

All 5 Releases


More Releases for Monoclonal

Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into
Global Monoclonal Antibody Diagnostic Reagents Market
Antibodies are an essential tool for many applications including flow cytometric analysis, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunocytochemistry, western blotting, and immunohistochemistry. Moreover, monoclonal antibodies (MAbs) are significant diagnostic reagent used in microbiological research, biomedical research, and also in diagnosis of various diseases such as HIV, hepatitis, herpes simplex, influenza infections, chlamydia, as well as for the treatment of cancer. Therefore, due to its importance in the clinical application, it
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.